High-dose curcuminoids are efficacious in the reduction in symptoms and signs of oral lichen planus - 16/04/12
, Erin Madden, MPH c, Francina Lozada-Nur, DDS, MS, MPH a, Sol Silverman, MA, DDS a
Reprint requests: Nita Chainani-Wu, DMD, MS, PhD, University of California, San Francisco, 521 Parnassus Ave, C646, Box 0658, San Francisco, CA 94143-0658.Abstract |
Background |
Curcuminoids are components of turmeric (Curcuma longa) that possess anti-inflammatory properties.
Objective |
We sought to study the efficacy of curcuminoids in controlling the signs and symptoms of oral lichen planus, at doses of 6000 mg/d (3 divided doses), and their safety at this dose.
Methods |
Twenty consecutive, eligible patients who consented were enrolled into this randomized, double-blind, placebo-controlled clinical trial in 2007 through 2008. Measurement of symptoms and signs of oral lichen planus using the Numerical Rating Scale (NRS) and the Modified Oral Mucositis Index (MOMI), respectively; complete blood counts; liver enzymes; C-reactive protein; and interleukin-6 levels was done at baseline and day 14. Two-sided P values are reported.
Results |
In the placebo group, the percentage changes from baseline in NRS (median [interquartile range] = 0.00 [−29 to 16.7], P > .99), erythema (0.00 [−10 to 16.7], P = .98), ulceration (0.00 [0.00 to 26.7], P = .63), and total MOMI scores (−3.2 [−13 to 9.09], P = .95) were not statistically significant, whereas they were statistically significant in the curcuminoids group: NRS (−22 [−33 to −14], P = .0078); erythema (−17 [−29 to −8.3], P = .0078), ulceration (−14 [−60 to 0.00], P = .063), MOMI (−24 [−38 to −11], P = .0039). The curcuminoids group showed a greater reduction in clinical signs and symptoms as compared with the placebo group, measured by percentage change in erythema (P = .05) and total MOMI score (P = .03), and proportion showing improvement in NRS (0.8 vs 0.3, P = .02) and total MOMI score (0.9 vs 0.5, P = .05). Adverse effects were uncommon in both groups.
Limitations |
The small sample size resulted in limited power, particularly for multivariate analyses.
Conclusions |
Curcuminoids at doses of 6000 mg/d in 3 divided doses are well tolerated and may prove efficacious in controlling signs and symptoms of oral lichen planus.
Le texte complet de cet article est disponible en PDF.Key words : anti-inflammatory, autoimmune, curcuminoids, herbal, oral lichen planus, turmeric
Abbreviations used : CRP, IL, MOMI, NRS, OLP, UCSF
Plan
| Supported by the Mount Zion Health Fund, through the Osher Center for integrative medicine, University of California, San Francisco. Sabinsa Corp (Dr Vladimir Badmaev, Piscataway, NJ) donated the curcuminoids and placebo capsules. |
|
| Conflicts of interest: None declared. |
Vol 66 - N° 5
P. 752-760 - mai 2012 Retour au numéro
Article précédent
- Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials
- Kenneth B. Gordon, Kim A. Papp, Richard G. Langley, Vincent Ho, Alexa B. Kimball, Cynthia Guzzo, Newman Yeilding, Philippe O. Szapary, Steven Fakharzadeh, Shu Li, Ming-Chun Hsu, Kristian Reich
- Treatment of erosive oral lichen planus with local ultraviolet B phototherapy
- Riad Kassem, Noam Yarom, Alon Scope, Meir Babaev, Henri Trau, Felix Pavlotzky
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?